Home >
Presentations
Text Size make text size smaller make text size largerPrint print this page

Presentations

Download a presentation for more information.
Adobe® Reader®

Phase I/II Study of Vosaroxin and Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
American Association of Cancer Research Annual Meeting 2014
San Diego, California
April 8th, 2014
Download (PDF,269KB)
VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.
American Society of Clinical Oncology 2012 Annual Meeting
Chicago, Illinois
June 4th, 2012
Download (PDF,364KB)
Adaptive Design of VALOR, a Phase 3 Trial of Vosaroxin or Placebo in Combination with Cytarabine for Patients With First Relapsed or Refractory Acute Myeloid Leukemia.
American Society of Clinical Oncology 2011 Annual Meeting
Chicago, Illinois
June 6th, 2011
Download (PDF,2.35MB)
Vosaroxin in AML.
Chemotherapy Foundation Symposium XXVIII
New York, New York
November 10th, 2010
Download (PDF,296KB)
Results of a phase 2 pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
American Society of Clinical Oncology 2010 Annual Meeting
Chicago, Illinois
June 7th, 2010
Download (PDF,166KB)
Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Results from a phase 2 study with three schedules.
American Society of Clinical Oncology 2010 Annual Meeting
Chicago, Illinois
June 7th, 2010
Download (PDF,174KB)
Final results of a phase 2 study of voreloxin in women with platinum-resistant ovarian cancer.
American Society of Clinical Oncology 2010 Annual Meeting
Chicago, Illinois
June 7th, 2010
Download (PDF,115KB)
Phase 1b/2 Pharmacokinetic/Pharmacodynamic Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory AML Patients.
The American Society of Hematology 2009
New Orleans, Louisiana
December 7th, 2009
Download (PDF,333KB)
A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
The American Society of Hematology 2009
New Orleans, Louisiana
December 5th, 2009
Download (PDF,176KB)
Clinical Evidence of Mechanism-Based Pharmacodynamic Activity in Voreloxin-Treated AML Patients.
AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
Boston, Massachusetts
November 18th, 2009
Download (PDF,253KB)
Voreloxin is Synergistic in In Vitro Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine.
AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
Boston, Massachusetts
November 18th, 2009
Download (PDF,190KB)
Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.
American Society of Clinical Oncology 2009 Annual Meeting
Orlando, Florida
June 1st, 2009
Download (PDF,550KB)
A phase II trial of voreloxin in women with platinum-resistant ovarian cancer.
American Society of Clinical Oncology 2009 Annual Meeting
Orlando, Florida
May 31st, 2009
Download (PDF,189KB)
A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).
American Society of Clinical Oncology 2009 Annual Meeting
Orlando, Florida
May 30th, 2009
Download (PDF,228KB)
Voreloxin is active in breast cancer biopsies and potency is enhanced in a BRCA2 mutant background
2009 American Association for Cancer Research (AACR)
Denver, Colorado
April 19th, 2009
Download (PDF,248KB)
Voreloxin as a Topoisomerase II Poison: Role of DNA Intercalation
2009 American Association for Cancer Research (AACR)
Denver, Colorado
April 19th, 2009
Download (PDF,165KB)
Phase 2 Study of Voreloxin (SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses
2008 American Society of Hematology Meeting and Exposition (ASH)
San Francisco, California
December 6th, 2008
Download (PDF,161KB)
Voreloxin in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1b/2 Study In Relapsed/Refractory Acute Myeloid Leukemia
2008 American Society of Hematology Meeting and Exposition (ASH)
San Francisco, California
December 6th, 2008
Download (PDF,142KB)
Voreloxin (SNS-595) in Platinum-Resistant Ovarian Cancer
Chemotherapy Foundation Symposium XXVI
New York City, New York
November 6th, 2008
Download (PDF,325KB)
Voreloxin (SNS-595): An Active Agent in AML
Chemotherapy Foundation Symposium XXVI
New York City, New York
November 5th, 2008
Download (PDF,770KB)
A Phase 2 Trial of Voreloxin (formerly SNS-595) in Women with Platinum-Resistant Ovarian Cancer
12th Biennial International Gynecological Cancer Society Meeting (IGCS)
Bangkok, Thailand
October 25th, 2008
Download (PDF,310KB)
Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle dependent DNA damage and rapid apoptosis in cancer cell lines
20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"
Geneva, Switzerland
October 24th, 2008
Download (PDF,498KB)
Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients ≥60 years old Compared to < 60 years old: Results of a Phase 1b Study
13th EHA Congress
Copenhagen, Denmark
June 14th, 2008
Download (PDF,200KB)
A Phase 2 Trial of Voreloxin (Formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer
44th ASCO Annual Meeting
Chicago, IL
May 31st, 2008
5582
Download (PDF,1.0MB)
Ex Vivo Activity of SNS-595 Against Biopsies of Acute Myeloid Leukemia, Triple Negative Breast and Ovarian Cancers Supports Ongoing and Potential Clinical Indications
2008 AACR Annual Meeting
San Diego, CA
April 14th, 2008
2830
Download (PDF,130KB)
Sensitivity to SNS-595 is Related to Activation of Double Strand DNA Break Repair Pathways Including Homologous Recombination
2008 AACR Annual Meeting
San Diego, CA
April 14th 2008
1859
Download (PDF,240KB)
SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning
2008 AACR Annual Meeting
San Diego, CA
April 14th 2008
1860
Download (PDF,260KB)
SNS-595: A cancer therapeutic and novel DNA damaging agent
New York Academy of Sciences Pharmacologic Regulation of DNA Damage Checkpoints to Treat Cancer
New York, NY
March 13th 2008
Download (PDF,1.45MB)
A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer
Society of Gynecologic Oncologists (SGO) 39th Annual Meeting on Women's Cancer
Tampa, FL
March 10th, 2008
Download (PDF,108K)
A Phase 1b Open-Label Study of the Novel DNA Replication Inhibitor SNS-595 in Refractory Acute Leukemia
The American Society of Hematology 2007
Atlanta, GA
December 10th, 2007
Download (PDF,242K)
SNS-595 demonstrates predictable, dose-proportional pharmacokinetics in three Phase 1 clinical studies
2007 AAPS Annual Meeting and Exposition
San Diego, CA
November 14, 2007 8:00 AM
Download (PDF,168K)
SNS-595 potentiates the in vivo anti-tumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts
AACR-NCI-EORTC International Conference on Molecular Targets
San Francisco, CA
October 24, 2007 12:30PM
Download (PDF,210K)
A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer
AACR-NCI-EORTC International Conference on Molecular Targets
San Francisco, CA
October 23, 2007 12:30PM
Download (PDF,134K)
SNS-595: Preliminary Results Of Two Phase 2 Second Line Studies In Lung Cancer
ECCO 14 - European Cancer Conference
Barcelona, Spain
September 24, 2007 8:00 AM
Download (PDF,130K)
Pharmacokinetic/Pharmacodynamic Correlation with Clinical Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute Leukemias Treated with SNS 595
12th Congress of the European Hematology Association
Vienna, Austria
June 9, 2007, 6:00 PM
Download (PDF,86K)
A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias
48th ASH Annual Meeting
Orange County Convention Center, Orlando FL
Sunday Dec 10, 2006, 8:00 AM - 9:00 PM
Abstract Number: 1962
Download (PDF,111K)
SNS-595 A Novel S-Phase Active Cytotoxic Acts Synergistically With Cytarabine To Reduce Bone Marrow Cellularity And Circulating Neutrophils
48th ASH Annual Meeting
Orange County Convention Center, Orlando FL
Sunday Dec 10, 2006, 8:00 AM - 9:00 PM
Abstract Number: 2321
Download (PDF,716K)
SNS-595 demonstrates Clinical Activity and Dose Proportional Pharmacokinetics (PK) in Two Phase 1 Clinical Studies
2006 ASCO Annual Meeting
Georgia World Congress Center, Atlanta, Georgia
June 4, 2006, 2:00 PM - 6:00 PM
Abstract Number: 3062
Download (PDF,709K)
SNS-595 Has Synergistic Activity In Vitro With DNA Damaging Agents And Antimetabolites
97th Annual AACR Meeting
Washington Convention Center, Washington D.C.
Monday, Apr 03, 2006, 8:00 AM -12:00 PM
Abstract Number: 2132
Download (PDF,458K)
SNS-595, A Novel S-Phase Active Cytotoxic, Exhibits Potent In Vitro And In Vivo Activities, And Has The Potential For Treating Advanced Hematologic Malignancies
97th Annual AACR Meeting
Washington Convention Center, Washington D.C.
Tuesday, Apr 04, 2006, 1:00 PM - 5:00 PM
Abstract Number: 4726
Download (PDF,488K)
A Phase 1 Trial Of Weekly SNS-595 In Patients (PTS) With Refractory Cancer
97th Annual AACR Meeting
Washington Convention Center, Washington D.C.
Monday, Apr 03, 2006, 1:00 PM - 5:00 PM
Abstract Number: 2913
Download (PDF,274K)
CYP450 Inhibition, Induction, Metabolism and Routes of Elimination of SNS-595, a Novel Cell Cycle Inhibitor Currently in Phase I Clinical Trials
AACR-NCI-EORTC International
Poster Session C
November 17, 2005
Download (PDF,583K)
Results of a Phase I Trial of SNS-595 in Patients with Advanced Solid Malignancies
AACR-NCI-EORTC International
Poster Session B
November 16, 2005
Download (PDF,367K)
SNS-595, A Novel Cell Cycle Inhibitor in Phase 1 Clinical Trials, Causes Tumor Regressions, Cell-Cycle Arrest, and Apoptosis in Murine Models of Cancer
96th Annual AACR Meeting
Anaheim, CA
April 16-20, 2005
Presenter: Ute Hoch, Ph.D.
Download (PDF,293K)
The Phase 1 Clinical Compound SNS-595 Acts During S-Phase and Causes a Sustained G2 Arrest
96th Annual AACR Meeting
Anaheim, CA
April 16-20, 2005
Presenter: Jennifer Hyde
Download (PDF,287K)
The potent cytotoxic agent SNS-595 causes a rapid onset of apoptosis during the S-phase of the cell cycle
96th Annual AACR Meeting
Anaheim, CA
April 16-20, 2005
Presenter: Jennifer Hyde
Download (PDF,344K)
ADMET and pharmacokinetic properties of SPC-595, a novel cell cycle inhibitory antineoplastic agent in non-clinical species
AACR
Orlando, FL
2004
Presenters: Ute Hoch, Marc J. Evanchik, Kaori Kondo, Yasuyuki Mizuki, Duncan H. Walker, Jeffrey A. Silverman
Non-clinical admet, pk, and biological activity of SNS-595, a novel cell cycle inhibitory antineoplastic agent
ISSX
Vancouver, Canada
2004
In vitro and in vivo activity of SPC-595, a novel cell cycle inhibitory cytotoxic in murine syngeneic and human xenograft tumor models
Download (PDF,195K)
BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics
Berlin, Germany
November 16-19, 2010
Download (PDF,620KB)
Investors & Media
Find complete financial information, news about Sunesis, and upcoming events.
Discoveries in Development
Sunesis is developing vosaroxin in both AML and ovarian cancer.